Clinical trial
Study Evaluating Etanercept and Methotrexate in Plaque Psoriasis
NCT00161655 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00161655 |
|---|---|
| Title | Study Evaluating Etanercept and Methotrexate in Plaque Psoriasis |
| Official title | A Multicenter, Open-label, Randomized, Pilot-study to Evaluate the Efficacy and Safety of the Combination of Etanercept (ETN) and Methotrexate and of Etanercept (ETN) Alone in Patients With Plaque Psoriasis Despite Methotrexate Therapy |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Psoriasis, Arthritis, Psoriatic |
| Intervention type | Drug |
| Interventions | Etanercept, Methotrexate |
| Enrollment | 60 |
| Start date | Apr 1, 2005 |
| Primary completion | Aug 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Sep 12, 2005 |
| Last update posted | Sep 28, 2009 |
| Countries | Denmark, Finland, Norway, Sweden |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: